Storia in 2 fonti

Biotech Plummets On Cancer Disappointment. What Happened?

Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.

Raccontata da

biopharmadive.com

investors.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 mesi fa

Biotech Plummets On Cancer Disappointment. What Happened?

Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.

originale

biopharmadive.com1 mesi fa

Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.

Leggi questa versione → originale

Timeline cronologica

martedì 2 giugno 2026·biopharmadive.com
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
martedì 2 giugno 2026·investors.com
Biotech Plummets On Cancer Disappointment. What Happened?
Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.